1 interaction related to aim-high
Combining high-dose niacin (1-2 g/day, typically extended-release) with atorvastatin or other statins increases the risk of myopathy and rhabdomyolysis. The HPS2-THRIVE trial documented a fourfold excess of myopathy when extended-release niacin was added to simvastatin-based therapy, and the AIM-HIGH trial showed no cardiovascular benefit from this combination.